VIVUS: Vivus signs international marketing agreement for MUSE and ALIBRA
JUN 20, 2000, M2 Communications - Mountain View, Calif. -- VIVUS, Inc. (NASDAQ:VVUS) today announced a distribution and marketing agreement granting Abbott Laboratories (NYSE: ABT) exclusive rights for MUSE (alprostadil) and ALIBRA
in select markets, including Europe, Japan, Australia, New Zealand, and South and Central America. Abbott also has the option to co-develop and license future VIVUS transurethral products for the treatment of male erectile dysfunction (ED)
VIVUS, Inc. is a leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. The Company developed and manufactures the drug MUSE and the medical device ACTIS, two innovations in the treatment of erectile dysfunction, also known as impotence. The Company has filed for regulatory approval with the FDA
and the European Agency for the Evaluation of Medicinal Products (EMEA) for ALIBRA, its second-generation drug for the treatment of ED, and expects marketing clearance by late 2000 or early 2001.
The Company anticipates initiating clinical studies with its female sexual dysfunction product, ALISTA, during 2000. VIVUS also has ongoing research and development programs in male erectile dysfunction and premature ejaculation.
Vivus corporate home page:
vivus.com
Vivus Investor home page:
vivusinvestor.net
|
